Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, AVITA Medical's Enterprise Value is $194.74 Mil.
AVITA Medical's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-34.17 Mil. Therefore, AVITA Medical's EV-to-EBIT ratio for today is -5.70.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, AVITA Medical's Enterprise Value is $194.74 Mil.
AVITA Medical's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-33.54 Mil. Therefore, AVITA Medical's EV-to-EBITDA ratio for today is -5.81.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, AVITA Medical's Enterprise Value is $194.74 Mil.
AVITA Medical's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $50.14 Mil. Therefore, AVITA Medical's EV-to-Revenue ratio for today is 3.88.
AVITA Medical Enterprise Value Historical Data
The historical data trend for AVITA Medical's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
AVITA Medical Annual Data
Trend
Jun14
Jun15
Jun16
Jun17
Jun18
Jun19
Jun20
Jun21
Dec22
Dec23
Enterprise Value
2,875.66
583.91
401.00
87.95
305.71
AVITA Medical Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
Enterprise Value
87.95
282.25
368.52
315.93
305.71
Competitive Comparison
For the Medical Devices subindustry, AVITA Medical's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AVITA Medical Enterprise Value Distribution
For the Medical Devices & Instruments industry and Healthcare sector, AVITA Medical's Enterprise Value distribution charts can be found below:
* The bar in red indicates where AVITA Medical's Enterprise Value falls into.
AVITA Medical Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
AVITA Medical's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AVITA Medical (NAS:RCEL) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
AVITA Medical's current Enterprise Value is $194.74 Mil.
AVITA Medical's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-34.17 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
AVITA Medical's current Enterprise Value is $194.74 Mil.
AVITA Medical's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-33.54 Mil.
AVITA Medical's current Enterprise Value is $194.74 Mil.
AVITA Medical's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $50.14 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AVITA Medical Enterprise Value Related Terms
Thank you for viewing the detailed overview of AVITA Medical's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
AVITA Medical (AVITA Medical) Business Description
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the U.S. with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 U.S. burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the U.S. region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the U.S.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RCEL has been successfully added to your 